Prostate Cancer - Results from #21820

Racial and socioeconomic disparities in the selection of prostate brachytherapy - Abstract November 21, 2013

Risk of biochemical recurrence and positive surgical margins in patients with pT2 prostate cancer undergoing radical prostatectomy - Abstract November 21, 2013

Chemotherapeutic inhibitors in the treatment of prostate cancer - Abstract November 21, 2013

Sedentarism and overweight as risk factors for the detection of prostate cancer and its aggressivenes - Abstract November 21, 2013

Prostatic atrophy: Its spatial proximity to carcinoma and intraepithelial neoplasia based on annotation of digital slides - Abstract November 21, 2013

Volumetric-modulated arc therapy for a pelvic lymph node metastasis from prostate cancer: A case report - Abstract November 21, 2013

Reduction in serum clusterin is a potential therapeutic biomarker in patients with castration-resistant prostate cancer treated with custirsen - Abstract November 21, 2013

Safety and antitumor efficacy of 153Sm-EDTMP and docetaxel administered sequentially to patients with metastatic castration-resistant prostate cancer - Abstract November 21, 2013

Holmium laser enucleation of the prostate is safe in patients with prostate cancer and lower urinary tract symptoms - A retrospective feasibility study - Abstract November 19, 2013

Ureteral injuries sustained during robotic assisted laparoscopic prostatectomy - Abstract November 19, 2013

Dosimetric effects of prone and supine positions on post-implant assessments for prostate brachytherapy - Abstract November 19, 2013

Low rates of bone mineral density measurement in Medicare beneficiaries with prostate cancer initiating androgen deprivation therapy - Abstract November 19, 2013

Prostate volumes derived from MRI and volume-adjusted serum prostate-specific antigen: Correlation with Gleason score of prostate cancer - Abstract November 19, 2013

Fully automated prostate segmentation on MRI: Comparison with manual segmentation methods and specimen volumes - Abstract November 19, 2013

Men (aged 40-49 years) with a single baseline prostate-specific antigen below 1.0 ng/mL have a very low long-term risk of prostate cancer: Results from a prospectively screened population cohort - Abstract November 19, 2013

Systematic review: Anal and rectal changes after radiotherapy for prostate cancer - Abstract November 19, 2013

PSA screening in New Zealand: Total population results and general practitioners' current attitudes and practices - Abstract November 19, 2013

Development of a peptide-based vaccine targeting TMPRSS2:ERG fusion-positive prostate cancer - Abstract November 19, 2013

A urologic oncology roundtable discussion: Issues to consider in choosing treatment for metastatic castration-resistant prostate cancer - Abstract November 19, 2013

Abiraterone acetate in combination with prednisone for the treatment of patients with metastatic castration-resistant prostate cancer: U.S. Food and Drug Administration Drug Approval Summary - Abstract November 19, 2013

Page 1092 of 1437